ABT263 and LXR mediate enhanced growth reduction of a colon cancer xenograft, a glioblastoma patient‐derived xenograft, and a BRAF V600E‐mutated melanoma xenograft in nude mice. Here, BRAF is linked to malignant colon neoplasm.